Skip to content
Veracyte® Investor Relations
Veracyte is a global diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company’s growing menu of diagnostic tests leverages advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment.
The company’s tests in lung cancer, prostate cancer, breast cancer, thyroid cancer, bladder cancer, and idiopathic pulmonary fibrosis are available to patients and its renal cancer and lymphoma subtyping tests are in development, the latter as a companion diagnostic. With Veracyte’s exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its genomic tests to patients worldwide. Veracyte is based in South San Francisco, California.

Veracyte® Investor Relations

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Veracyte to Present at Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 2, 2021-- Details of the Raymond James Human Health Innovation Conference have been corrected. The updated release reads: VERACYTE TO PRESENT AT UPCOMING INVESTOR CONFERENCES Veracyte, Inc . (Nasdaq: VCYT), a global genomic diagnostics company,
View HTML
Toggle Summary *UPDATED WITH NEW TIME**: Veracyte to Present at the 2018 UBS Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 9, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson , chairman and chief executive officer, will present at the 2018 UBS Global Healthcare Conference on Wednesday, May 23, 2018 at 9:00 a.m. Eastern Time in New York, NY .
View HTML

Events

There are currently no events to display.

Presentations

Title Documents

Corporate Presentation November 2022